Journal of Pediatrics
May 2016 Volume 172, p1-236
http://www.jpeds.com/current

.
Editor’s Persepctive
Lest we forget — the battle against malnutrition
Carlos A. Cuello-Garcia
p1–4
Published in issue: May 2016
Preview
We are now living in an era of postmillennium development goals and, although a significant number of them have been completed, a significant proportion of targets remain to be accomplished. Malnutrition is still a concern that affects millions worldwide. In this issue of The Journal, Chowdhury et al present a large scale population-based survey in Bangladesh, extracted from the Bangladesh Demographic Health Survey (2011). This could be considered a large and representative sample of a region where prevention of malnutrition is (and it should be kept as) a priority as a public health intervention.

.
Original Articles
Risk Factors for Child Malnutrition in Bangladesh: A Multilevel Analysis of a Nationwide Population-Based Survey
Mohammad Rocky Khan Chowdhury, Mohammad Shafiur Rahman, Mohammad Mubarak Hossain Khan, Mohammad Nazrul Islam Mondal, Mohammad Mosiur Rahman, Baki Billah
p194–201.e1
Published online: February 5 2016

.
Original Articles
Sustained Effectiveness of Monovalent and Pentavalent Rotavirus Vaccines in Children
Lilly Cheng Immergluck, Trisha Chan Parker, Shabnam Jain, Elham Laghaie, Philip Spandorfer, Robert C. Jerris, Michael D. Bowen, Umesh D. Parashar, Margaret M. Cortese
p116–120.e1
Published online: February 27 2016
Abstract
Objective
Using case-control methodology, we measured the vaccine effectiveness (VE) of the 2-dose monovalent rotavirus vaccine (RV1) and 3-dose pentavalent rotavirus vaccine (RV5) series given in infancy against rotavirus disease resulting in hospital emergency department or inpatient care.
Study design
Children were eligible for enrollment if they presented to any 1 of 3 hospitals in Atlanta, Georgia with diarrhea ≤10 days duration during January-June 2013 and were born after RV1 introduction. Stool samples were tested for rotavirus by enzyme immunoassay and immunization records were obtained from providers and the state electronic immunization information system. Case-subjects (children testing rotavirus antigen-positive) were compared with children testing rotavirus antigen-negative.
Results
Overall, 98 rotavirus-case subjects and 175 rotavirus-negative controls were enrolled. Genotype G12P[8] predominated (n = 87, 89%). The VE of 2 RV1 doses was 84% (95% CI 38, 96) among children aged 8-23 months and 82% (95% CI 41, 95) among children aged ≥24 months. For the same age groups, the VE of 3 RV5 doses was 80% (95% CI 27, 95) and 87% (95% CI 22, 98), respectively.
Conclusions
Under routine use, the RV1 and RV5 series were both effective against moderate-to-severe rotavirus disease during a G12P[8] season, and both vaccines demonstrated sustained protection beyond the first 2 years of life.